140 related articles for article (PubMed ID: 38537338)
1. The design, synthesis and bioactivity evaluation of novel androgen receptor degraders based on hydrophobic tagging.
Sun Y; Wang H; Li Y; Li Z; Mao Z; Zhang M; Shao Y; Ye J; Li D; Shan L
Bioorg Chem; 2024 May; 146():107309. PubMed ID: 38537338
[TBL] [Abstract][Full Text] [Related]
2. Targeting androgen receptor degradation with PROTACs from bench to bedside.
Jia X; Han X
Biomed Pharmacother; 2023 Feb; 158():114112. PubMed ID: 36508999
[TBL] [Abstract][Full Text] [Related]
3. Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
Chen L; Han L; Mao S; Xu P; Xu X; Zhao R; Wu Z; Zhong K; Yu G; Wang X
Eur J Med Chem; 2021 Apr; 216():113307. PubMed ID: 33652354
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
6. Discovery of
Zhang B; Liu C; Yang Z; Zhang S; Hu X; Li B; Mao M; Wang X; Li Z; Ma S; Zhang S; Qin C
J Med Chem; 2023 Aug; 66(16):11158-11186. PubMed ID: 37556600
[TBL] [Abstract][Full Text] [Related]
7. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
Han X; Wang C; Qin C; Xiang W; Fernandez-Salas E; Yang CY; Wang M; Zhao L; Xu T; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Jan; 62(2):941-964. PubMed ID: 30629437
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
Gustafson JL; Neklesa TK; Cox CS; Roth AG; Buckley DL; Tae HS; Sundberg TB; Stagg DB; Hines J; McDonnell DP; Norris JD; Crews CM
Angew Chem Int Ed Engl; 2015 Aug; 54(33):9659-62. PubMed ID: 26083457
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Strategies to Target the Androgen Receptor.
Xiang W; Wang S
J Med Chem; 2022 Jul; 65(13):8772-8797. PubMed ID: 35786895
[TBL] [Abstract][Full Text] [Related]
10. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives.
Ha S; Luo G; Xiang H
J Med Chem; 2022 Dec; 65(24):16128-16154. PubMed ID: 36459083
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
13. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.
Takwale AD; Jo SH; Jeon YU; Kim HS; Shin CH; Lee HK; Ahn S; Lee CO; Du Ha J; Kim JH; Hwang JY
Eur J Med Chem; 2020 Dec; 208():112769. PubMed ID: 32961381
[TBL] [Abstract][Full Text] [Related]
14. Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer.
Hung CL; Liu HH; Fu CW; Yeh HH; Hu TL; Kuo ZK; Lin YC; Jhang MR; Hwang CS; Hsu HC; Kung HJ; Wang LY
EBioMedicine; 2023 Apr; 90():104500. PubMed ID: 36893587
[TBL] [Abstract][Full Text] [Related]
15. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Xiang W; Zhao L; Han X; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Kirchhoff PD; Wang L; Matvekas A; He M; Wen B; Sun D; Wang S
J Med Chem; 2021 Sep; 64(18):13487-13509. PubMed ID: 34473519
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
Wang A; Luo X; Wang Y; Meng X; Lu Z; Yang Y
J Med Chem; 2022 Sep; 65(18):12460-12481. PubMed ID: 36070471
[TBL] [Abstract][Full Text] [Related]
17. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
Han X; Zhao L; Xiang W; Qin C; Miao B; McEachern D; Wang Y; Metwally H; Wang L; Matvekas A; Wen B; Sun D; Wang S
J Med Chem; 2021 Sep; 64(17):12831-12854. PubMed ID: 34431670
[TBL] [Abstract][Full Text] [Related]
18. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
19. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
20. Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.
Tesei A; Leonetti C; Di Donato M; Gabucci E; Porru M; Varchi G; Guerrini A; Amadori D; Arienti C; Pignatta S; Paganelli G; Caraglia M; Castoria G; Zoli W
PLoS One; 2013; 8(5):e62657. PubMed ID: 23667504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]